Quantcast

Latest Cetuximab Stories

2014-10-30 08:37:13

Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers IRVING, Texas, Oct. 30, 2014 /PRNewswire/ -- Caris Life Sciences today announced the presentation of data from two large studies in which Caris Molecular Intelligence(TM), the company's panomic, comprehensive tumor profiling service, facilitated the molecular analysis of lung tumors. The biomarker...

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed oncologists in Argentina and Mexico are primarily prescribing biomarker-driven agents for the treatment of HER2-positive breast cancer and EGFR-mutation positive metastatic, non-small-cell lung cancer (NSCLC). However,...

2014-10-21 08:33:34

-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment RIDGEFIELD, Conn., Oct. 21, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced enrollment of the first patient in a new global Phase III study in patients with metastatic colorectal cancer (mCRC). Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases...

2014-09-29 08:30:18

BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options. SIR-Spheres Y-90 resin microspheres, the lead...

2014-09-12 08:25:08

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA(TM)) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab...

2014-09-02 16:25:30

AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix(TM). Xilonix, a True Human(TM) monoclonal antibody therapy, is being evaluated in advanced colorectal cancer patients where disease is further complicated with cachexia. The primary endpoint of the study is overall survival, comparing survival in Xilonix treated patients to a control population provided...

2014-08-28 12:30:01

Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 28, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The biosimilar erosion of...

2014-08-01 16:23:45

AUSTIN, Texas, Aug. 1, 2014 /PRNewswire/ -- XBiotech has enrolled the first patient into its European Phase III study using its novel cancer drug Xilonix(TM) for the treatment of colorectal cancer. The double-blinded placebo controlled study is evaluating the use of the monoclonal antibody therapy designed to block chronic inflammation associated with malignant tumor growth. The treatment is reportedly aimed at reversing disease symptoms associated with disease progression and...

First Antibodies To Treat Cancer In Dogs Developed
2014-07-07 03:10:21

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time,...

2014-06-30 13:06:13

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,"...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related